1 / 3

PPT NEW

The experts from the US FDA say that oral decongestant pills with phenylephrine (called PE) do not work well for stuffy noses because they break down before getting into your body. They want to change how these pills are labeled to stop people from being misled. This might make companies change their products. A group that represents these companies is worried about this. But scientists and researchers are happy about the findings. In 2022, PE pills made $1.76 billion in the US, while better options like pseudoephedrine (called PSE) made $542 million. It's important to educate consumers so the

Aishwarya32
Télécharger la présentation

PPT NEW

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ineffectiveness of Oral Decongestant Ingredient Highlighted by FDA Panel WhatsApp : +44(782)-201-3567 (UK) +1(646)631-6696 (USA) +91-904-002-3003 (India Email id : support@manuscriptedit.com

  2. Oral phenylephrine-based (PE) decongestants, widely used for nasal congestion, have been deemed ineffective by a US FDA expert panel after analyzing clinical trials. The medicine fails to alleviate nasal stuffiness when ingested due to significant breakdown before entering the bloodstream. Consequently, the panel recommends reclassifying oral PE decongestants to prevent misleading labeling. This may compel manufacturers to reformulate popular products. While the FDA’s response is pending, a trade organization representing manufacturers expresses concern. In contrast, scientists and researchers welcome the findings. In 2022, PE decongestants generated $1.76 billion in sales in the US, while effective alternatives like pseudoephedrine (PSE) made $542 million. Consumer education is crucial for choosing appropriate alternatives.

  3. THANK YOU

More Related